SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft.The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing extreme volatility following its massive IPO as investors debate the impact of the newly announced $60 billion all-stock acquisition of AI startup Cursor. Community discussion remains polarized, with bulls betting on aggressive growth and Elon Musk's long-term vision, while skeptics are pointing to significant dilution concerns, the lack of current profitability, and a tight initial float that has created a hot-potato environment.

Rackspace Technology, Inc. engages in the provision of end-to-end multi-cloud technology services. The firm designs, builds and operates its customers’ cloud environments across technology platforms. It operates through the following segments: Multicloud Services and Apps & Cross Platform. The Multicloud Services segment includes public and private cloud managed services offerings, as well as professional services related to designing and building multicloud solutions and cloud-native applications. The Apps & Cross Platform segment includes managed applications, managed security and data services, as well as professional services related to designing and implementing application, security and data services. The company was founded on July 21, 2016 and is headquartered in San Antonio, TX.

Rackspace Technology Inc

Rackspace Technology is seeing intense community speculation as investors debate the impact of its recent workforce realignment and new AI compute agreement with AMD. While some participants are optimistic about a potential re-rating driven by AI growth and cost-saving measures, others are cautious, actively discussing the possibility of a share offering and the impact of the company's debt levels on future performance.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is facing intense downward pressure and widespread investor skepticism following earnings that fell short of analyst expectations, sparking intense debate over the company's long-term viability and potential for bankruptcy. While some bargain hunters see a potential recovery play or buyout candidate given the heavily shorted interest, others remain deeply bearish, citing failing foot traffic, poor management execution, and an unsustainable debt load as reasons to avoid the stock.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is under heavy community scrutiny as investors brace for the final data readout from its Phase 3 REGAL trial, with intense debate centered on the upcoming vote for a 20 million share RSU expansion. While bulls argue that the extended trial duration and recent protocol adjustments indicate strong patient survival and a potentially curative treatment for AML, bears and skeptics are voicing significant concerns regarding potential shareholder dilution and the historical failure of similar cancer vaccine programs.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is experiencing significant momentum alongside broader memory and storage sector leaders, driven by intense institutional demand for data center infrastructure and artificial intelligence workloads. The community remains highly active, debating the sustainability of these record-breaking valuation re-ratings and the potential for a long-term cyclical supercycle versus concerns of a temporary bubble.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. The company operates through the OSS and OSS Europe segments. One Stop Systems was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing massive investor enthusiasm following a strong earnings report that highlighted record bookings, high gross margins, and growth in its edge computing and defense pipelines. The community is actively discussing the stock's low float and the potential for a significant re-rating as institutional interest grows and investors wait for upcoming military contract announcements.

Syntec Optics Holdings, Inc. engages in the design and manufacture of optics and photonics enabled products. The company was founded in 1981 and is headquartered in Rochester, NY.

Syntec Optics Holdings Inc. - Ordinary Shares - Class A

Syntec Optics Holdings Inc

Syntec Optics (OPTX) is trending as investors capitalize on its role as a strategic domestic supplier for high-growth sectors like defense, AI data-center optics, and LEO satellite infrastructure. The community is heavily focused on the company's scaling production capacity, potential for future contract awards within the Anduril-led defense ecosystem, and the low-float nature of the stock, which has led to intense speculation about long-term upside potential and volatility.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to Hantavirus outbreak concerns, with community discussion centered on the company's mRNA platform potential and the volatility often associated with pandemic-related trading. Market participants are actively debating the sustainability of the recent upward momentum while closely monitoring new health updates and institutional accumulation patterns.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye is generating significant buzz following strong Q1 results, a raised revenue outlook, and a new $250 million share buyback program. The community is actively debating the stock's potential for a short squeeze against its depressed valuation, while simultaneously highlighting long-term optimism surrounding its pivot into robotics and expansion in the autonomous robotaxi sector.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz as investors brace for pivotal 52-week data, with the community actively speculating on a potential buyout as trial milestones align with upcoming investor conferences. Investors are closely monitoring clinical trial updates and corporate signaling, viewing the current period as a strategic 'watch and wait' phase before a anticipated catalyst-driven repricing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire NEW YORK, June 4, 2026 NEW YORK, June 4, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire NEW YORK, May 28, 2026 NEW YORK, May 28, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA PR Newswire NEW YORK, May 14, 2026 NEW YORK, May 14, 2026...

Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics stock plunged after the Duchenne trial data missed investor expectations despite positive functional improvement signals.read more...

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +10.59% and -86.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?

Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) insider Natarajan Sethuraman sold 25,907 shares of the company's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $15.39, for a total value of $398,708.73. Following the transaction, the insider...

Entrada Therapeutics (NASDAQ:TRDA) COO Nathan Dowden Sells 15,000 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) COO Nathan Dowden sold 15,000 shares of the firm's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating...

Travere Therapeutics (TVTX) Reports Q1 Loss, Misses Revenue Estimates

Travere (TVTX) delivered earnings and revenue surprises of -30.74% and -1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Entrada Therapeutics (NASDAQ:TRDA) Trading 7.6% Higher - Should You Buy?

Entrada Therapeutics (NASDAQ:TRDA) Stock Price Up 7.6% - What's Next...

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.05	--	--	N/A
Q1 '26	-$1.04	-$0.95	8.36%	BEAT
Q4 '25	-$1.15	-$0.94	18.28%	BEAT
Q3 '25	-$0.94	-$1.06	-12.77%	MISSED
Q2 '25	-$0.85	-$1.04	-22.76%	MISSED

TRDAEntrada Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest TRDA News